Healthcare
Live Price
Offline$0.0005
+25.00% today
1Y Change
-99.62%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 220 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
T2 Biosystems, Inc. (TTOO) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 99.6% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -67.8%, EPS growth of +98.4%, a dividend yield of 0.0%. What stands out right now is revenue -67.8%, EPS +98.4%, free cash flow +5.2% with operating margin -690.4% and ROIC -230.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TTOO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TTOO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TTOO Max Drawdown
-99.93%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TTOO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$8.3M
-54.0% YoY
FY Net Income
-$59.0M
-26.1% YoY
Free Cash Flow
-$46.1M
-4.8% YoY
Revenue Growth
-67.8%
EPS Growth
+98.4%
Gross Margin
-113.6%
Net Margin
-696.2%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 7M | 22M | 28M | 18M | 8M |
| Gross Profit | -8M | 1M | 7M | -3M | -8M |
| Operating Income | -50M | -54M | -43M | -41M | -52M |
| EBITDA | -44M | -55M | -41M | -37M | -48M |
| Net Income | -50M | -62M | -49M | -47M | -59M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 16M | 10M | 22M | 17M | 11M |
| Total Assets | 35M | 34M | 61M | 79M | 28M |
| Total Liabilities | 63M | 74M | 73M | 70M | 62M |
| Shareholder Equity | -28M | -40M | -13M | 9M | -34M |
| Total Debt | 49M | 59M | 58M | 57M | 45M |
| Net Debt | 34M | 49M | 36M | 39M | 34M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
45M
-5.0% YoY
Capital Expenditures
761K
+5.3% YoY
Free Cash Flow
46M
-4.8% YoY
Key ratios
Gross Margin
-113.6%
Operating Margin
-690.4%
Net Margin
-696.2%
ROE
147.3%
Debt / Equity
-1.77x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.